347 related articles for article (PubMed ID: 23767798)
1. Mesalazine for the treatment of inflammatory bowel disease.
Criscuoli V; Modesto I; Orlando A; Cottone M
Expert Opin Pharmacother; 2013 Aug; 14(12):1669-78. PubMed ID: 23767798
[TBL] [Abstract][Full Text] [Related]
2. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
Clemett D; Markham A
Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042
[TBL] [Abstract][Full Text] [Related]
3. The pharmacological profile and clinical use of mesalazine (5-aminosalicylic acid).
Klotz U
Arzneimittelforschung; 2012 Feb; 62(2):53-8. PubMed ID: 22344548
[TBL] [Abstract][Full Text] [Related]
4. Drug insight: aminosalicylates for the treatment of IBD.
Nielsen OH; Munck LK
Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
[TBL] [Abstract][Full Text] [Related]
5. Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis.
Harris MS; Lichtenstein GR
Aliment Pharmacol Ther; 2011 May; 33(9):996-1009. PubMed ID: 21385194
[TBL] [Abstract][Full Text] [Related]
6. Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties.
Tromm A; Griga T; May B
Hepatogastroenterology; 1999; 46(30):3124-35. PubMed ID: 10626173
[TBL] [Abstract][Full Text] [Related]
7. Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.
Prakash A; Markham A
Drugs; 1999 Mar; 57(3):383-408. PubMed ID: 10193690
[TBL] [Abstract][Full Text] [Related]
8. [5-aminosalicylic acid in the treatment of ulcerative colitis and Crohn's disease].
Moum B
Tidsskr Nor Laegeforen; 2003 Sep; 123(18):2565-7. PubMed ID: 14714043
[TBL] [Abstract][Full Text] [Related]
9. Review article: aminosalicylates in inflammatory bowel disease.
Hanauer SB
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():60-5. PubMed ID: 15352896
[TBL] [Abstract][Full Text] [Related]
10. [Medical therapy of inflammatory bowel diseases: ulcerative colitis].
Lakatos L; Lakatos PL
Orv Hetil; 2007 Jun; 148(25):1163-70. PubMed ID: 17573252
[TBL] [Abstract][Full Text] [Related]
11. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
Lichtenstein GR; Kamm MA; Sandborn WJ; Lyne A; Joseph RE
Aliment Pharmacol Ther; 2008 Jun; 27(11):1094-102. PubMed ID: 18363894
[TBL] [Abstract][Full Text] [Related]
12. Controversies with aminosalicylates in inflammatory bowel disease.
Lim WC; Hanauer SB
Rev Gastroenterol Disord; 2004; 4(3):104-17. PubMed ID: 15359211
[TBL] [Abstract][Full Text] [Related]
13. Systematic review: the use of mesalazine in inflammatory bowel disease.
Bergman R; Parkes M
Aliment Pharmacol Ther; 2006 Apr; 23(7):841-55. PubMed ID: 16573787
[TBL] [Abstract][Full Text] [Related]
14. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial.
Reinisch W; Angelberger S; Petritsch W; Shonova O; Lukas M; Bar-Meir S; Teml A; Schaeffeler E; Schwab M; Dilger K; Greinwald R; Mueller R; Stange EF; Herrlinger KR;
Gut; 2010 Jun; 59(6):752-9. PubMed ID: 20551460
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics of slow release mesalazine.
De Vos M
Clin Pharmacokinet; 2000 Aug; 39(2):85-97. PubMed ID: 10976656
[TBL] [Abstract][Full Text] [Related]
16. The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease.
Bonapace CR; Mays DA
Ann Pharmacother; 1997; 31(7-8):907-13. PubMed ID: 9220055
[TBL] [Abstract][Full Text] [Related]
17. Multi-Matrix System (MMX®) mesalamine for the treatment of mild-to-moderate ulcerative colitis.
Horst SN; Kane S
Expert Opin Pharmacother; 2012 Oct; 13(15):2225-32. PubMed ID: 22970981
[TBL] [Abstract][Full Text] [Related]
18. Combined butyric acid/mesalazine treatment in ulcerative colitis with mild-moderate activity. Results of a multicentre pilot study.
Assisi RF;
Minerva Gastroenterol Dietol; 2008 Sep; 54(3):231-8. PubMed ID: 18614971
[TBL] [Abstract][Full Text] [Related]
19. Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease.
Mulder CJ; van den Hazel SJ
Mediators Inflamm; 1998; 7(3):135-6. PubMed ID: 9705596
[TBL] [Abstract][Full Text] [Related]
20. Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids.
Bello C; Belaiche J; Louis E; Reenaers C
J Crohns Colitis; 2011 Jun; 5(3):196-202. PubMed ID: 21575881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]